Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]10/15 15:30TDnetPDF(515KB)
Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib9/24 17:30TDnetPDF(300KB)
Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML8/25 11:30TDnetPDF(276KB)
Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor7/28 15:30TDnetPDF(274KB)
Non-consolidated Financial Results for the Nine Months Ended May 31 2026 [Japanese GAAP]7/15 15:30TDnetPDF(272KB)